BIOSPECIFICS TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-11-21: Form 8-K; Period of report 2019-11-19; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2019-10-23: Form 8-K; Period of report 2019-10-21; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2019-10-10: Form 8-K; Period of report 2018-10-11; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2019-08-22: Form 8-K; Period of report 2019-08-22; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-11-21 | 8-K | 2019-11-19 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As disclosed in Item 5.02 of the Current Report on Form 8-K filed by the Company on October 10, 2019, the Company’s Board of Directors (the “Board”) appointed J. Kevin Buchi as Chief Executive Officer of the Company and to the Board, effective as of October 8, 2019. | d838365d8k.htm |
| 2019-10-23 | 8-K | 2019-10-21 | 7.01 Regulation FD Disclosure | 7.01 On October 23, 2019, the Company issued a press release announcing that on October 21, 2019, the Board of Directors (the “Board”) of the Company elected Jennifer Chao to serve as the chairperson of the Board, effective immediately. | d821010d8k.htm |
| 2019-10-10 | 8-K | 2018-10-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 10, 2019, the Company announced that its Board of Directors (the “Board”) appointed J. Kevin Buchi as Chief Executive Officer of the Company, effective as of October 8, 2019 (the “Effective Date”). | form8k.htm |
| 2019-08-22 | 8-K | 2019-08-22 | 7.01 Regulation FD Disclosure | 7.01 Beginning August 22, 2019, officers and representatives of the Company will present to various investors and stockholders using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2019-08-09 | 8-K | 2019-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2019, the Company announced its financial and operating results for the fiscal quarter ended June 30, 2019. | form8k.htm |
| 2019-06-14 | 8-K | 2019-06-14 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2019 annual meeting of stockholders of the Company (the “2019 Annual Meeting”) was held on June 13, 2019. | form8k.htm |
| 2019-05-23 | 8-K | 2019-05-23 | 8.01 Other Events | 8.01 On May 23, 2019, the Company announced that the Executive Committee of its Board of Directors had approved a new authorization under the Company's previously announced stock repurchase program for the repurchase of up to $4.0 million of the Company's outstanding common stock. | form8k.htm |
| 2019-05-10 | 8-K | 2019-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2019, the Company announced its financial and operating results for the fiscal quarter ended March 31, 2019. | form8k.htm |
| 2019-04-02 | 8-K | 2019-04-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 1, 2019 (the "Effective Date"), the Company appointed (i) Dr. Ronald Law to the role of Principal Executive Officer of the Company and (ii) Mr. Pat Caldwell to the role of Principal Financial Officer, assuming both the principal financial officer and principal accounting officer functions on an interim basis pending an executive search being conducted by the Company. | form8k.htm |
| 2019-04-02 | 8-K | 2019-04-02 | 2.02 Results of Operations and Financial Condition | 2.02 On April 2, 2019, the Company announced its financial and operating results for the fiscal quarter and full year ended December 31, 2018. | form8k.htm |
| 2019-03-18 | 8-K | 2019-03-18 | 8.01 Other Events | 8.01 On March 18, 2019, the Company issued a press release that announced, with great sadness, that Thomas L. Wegman, President of the Company, passed away on March 13, 2019. | form8k.htm |
| 2019-02-28 | 8-K | 2019-02-21 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | form8k.htm |
| 2019-02-21 | 8-K | 2019-02-21 | 8.01 Other Events | 8.01 The Company will hold its 2019 annual meeting of stockholders (the “Annual Meeting”) on Thursday, June 13, 2019 at 11:00 a.m. | form8k.htm |
| 2019-01-24 | 8-K | 2019-01-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On January 23, 2019 (the “Effective Date”), the Company announced that (i) Dr. Ronald Law, the Company’s Senior Vice President of Business Development, would be assisting Mr. Thomas L. Wegman, the Company’s President, with day-to-day operations of the Company and (ii) the Company’s Board of Directors has designated Dr. Law as an executive officer of the Company, as of the Effective Date. 8.01 On the Effective Date, Mr. Thomas L. Wegman issued a letter to colleagues and shareholders updating them on his medical condition. | form8k.htm |